PureMalt selects Epicor to provide better data visibility
Business software solutions company Epicor has announced that PureMalt has chosen the Epicor Tropos ERP solution to streamline its processes and allow better transparency of data.
PureMalt develops various refined malt extrants which are used extensively in the food and drink industry, and has expanded over the past 40 years from flour milling to specialised production of malt extracts that are exported to over 60 countries.
The company has grown to the point where it needs an ERP solution which can manage all operational processes in one streamlined system. PureMalt previously used various outdated software applications, including Access database platforms and Excel spreadsheets, and this had remained unchanged since the mid-1990s.
Ross Turner, Business Systems Manager at PureMalt said: “We had grown to a size that we saw as a critical mass for future growth, but we didn’t have a major supporting system in place for the business. We needed an ERP system that could provide us with accurate real-time business data because we wanted to have better visibility of the business performance as well as streamline and improve the different processes.”
What set Tropos apart was the fact that it is a software platform that is clearly born out of a production and manufacturing focus, whereas some of its competitors’ products seem to have grown out of a finance-focused package. The manufacturing focus is key to supporting the growth of our business and how we compete with our counterparts,” turner added.
Epicor Tropos is a process manufacturing solution that provides unrivalled recipe-based production, materials traceability, and regulatory compliance for UK process manufacturers. It offers organisations the power to improve decision making, strengthen internal and external connections, deliver on shorter production and supply schedules, and gain business efficiency and cost savings.
IMF: Variants Can Still Hurt Manufacturing Recovery
After a year of on-and-off manufacturing in the US, UK, and the eurozone, demand for goods surged early last week. Factories set growth records in April and May, suppliers started to recover, and US crude hit its highest price point since pre-COVID. As vaccination efforts immunise much of the US and UK populations, manufacturers are now able to fully ramp up their supply chains. In fact, GDP growth could approach double-digits by 2022.
Now, the ISM productivity measure has surpassed the 50-point mark that separates industry expansion from contraction. Since U.S. president Biden passed his US$1.9tn stimulus package and the UK purchasing managers index (PMI) increased to 65.6, both sides of the Atlantic are facing a much-welcomed manufacturing recovery.
Lingering Concerns Over COVID
Even as Spain, France, Italy, and Germany race to catch up, and mining companies pushed the FTSE 100 index of list shares to a monthly high of 7,129, some say that UK and US markets still suffer from a lack of confidence in raw material supplies. Yes, the Dow Jones has made up its 19,173-point crash of March 2020, and MSCI’s global stock index is at an all-time high.
Yet manufacturers around the world realise that these wins will be short-lived until pandemic supply chain bottlenecks are solved. If we keep the status quo, consumers will pay the price. In April, inflation in Germany reached 2.4%, and across the EU’s 19 member countries, overall prices have increased at an unusual pace. Some ask: Is this true recovery?
IMF: Current Boom Could Falter
Even as Elon Musk tweeted about chip shortages forcing Tesla to raise its prices, UK mining demand skyrocketed; housing markets lifted; and the pound sterling gained value. The International Monetary Fund (IMF), however, cautioned that manufacturing recovery won’t last long if COVID mutates into forms our vaccinations can’t touch. Kristalina Georgieva, Washington’s IMF director, noted that fewer than 1% of African citizens have been vaccinated: “Worldwide access to vaccines offers the best hope for stopping the coronavirus pandemic, saving lives, and securing a broad-based economic recovery”.
Across the globe, manufacturing companies are keeping a watchful eye on new developments in the spread of COVID. Though US FDA officials don’t think we’ll have to “start at square one” with new vaccines, the March 2021 World Economic Outlook states that “high uncertainty” surrounds the projected 6% global growth. Continued manufacturing success will in large part depend on “the path of the pandemic, the effectiveness of policy support, and the evolution of financial conditions”.
Mathias Cormann, secretary-general of the Organisation for Economic Co-Operation and Development (OECD) concurred—without global immunisation, the estimated economic boom expected by 2025 could go kaput. “We need to...pursue an all-out effort to reach the entire world population”, Australia’s finance minister added. US$50bn to end COVID across the world, they imply, is a small investment to restart our economies.